Case Studies

Drawing on expertise from its regulatory, gene therapy and manufacturing consultants, Alacrita conducted feasibility study and formulated a business case for a new GMP facility for production of...

Oncology company with a preclinical project seeking finance and potential acquisition For a virtual life science company, Alacrita helped establish a valuation trajectory for one of their products,...

On behalf of a private equity (PE) investor, an Alacrita partner was retained as an observer on the board of a regenerative medicine/advanced wound healing company where he contributed to BoD...

Asset scouting for a well-capitalized Swiss pharma company Alacrita been engaged by a well-capitalized Swiss pharma company to scout and identify early stage in-licensing opportunities from the New...

Challenge: An emerging specialty pharma company facing an urgent partnering transaction deadline needed to assess the likely reimbursement and pricing of a new therapy in a crowded haematology...

A venture-backed biotech company, developing a clinical stage asset for the treatment of early stage cancer, was populating a dataroom and preparing for negotiations with a major pharmaceutical...

Alacrita’s antibody consultants were engaged to help a start-up company that had developed a suite of proprietary antibody technologies to identify accessible cell surface proteins for discovery of...